diagnostic and prognostic importance of venous thromboembolism in ovarian cancer

Clicks: 258
ID: 207796
2007
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #66 of 231 articles by views in planta medica

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 231 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract

Background: Cancer and its chemotherapy are well known risk factors for venous thromboembolism. The later can be the first sign of an occult malignancy, especially if it is recurrent one. Venous thromboembolism is also a common cause of morbidity and mortality among cancer patients. In time of the first presentation of venous thromboembolism in the context of underlying cancer the advanced stage of cancer is usually present and this is associated with poor prognosis. Ovarian cancer which is diagnosed within four months after an episode of venous thromboembolism is usually in advanced stages with more aggressive biological properties.

Conclusions: Low-molecular-weight-heparins are the cornerstone of treatment and prophylaxis of venous thromboembolism associated with cancer for the first 3 to 6 months after acute venous thromboembolic event. In accordance with current consensus they are replaced with oral anticoagulants after 6 months of treatment. According to recent trials lowmolecular- weight-heparins cause less side effects and there are less recurrent venous throm  boembolisms than with peroral anticoagulant therapy. Accordingly their impact on improved survival of cancer patients is under intensive research. Unfortunately, there is currently no screening test for ovarian cancer which would lead to improved survival.

Reference Key
kupnik2007zdravnikidiagnostic Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Dejan Kupnik;Iztok Takač
Journal planta medica
Year 2007
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.